دورية أكاديمية
أعرض في EDS

MyD88 Signaling Accompanied by Microbiota Changes Supports Urinary Bladder Carcinogenesis.

التفاصيل البيبلوغرافية
العنوان: MyD88 Signaling Accompanied by Microbiota Changes Supports Urinary Bladder Carcinogenesis.
المؤلفون: Knezović D; Laboratory for Cancer Research, University of Split School of Medicine, Šoltanska 2A, 21000 Split, Croatia., Milić Roje B; Laboratory for Cancer Research, University of Split School of Medicine, Šoltanska 2A, 21000 Split, Croatia., Vilović K; Department of Pathology, Forensic Medicine and Cytology, University Hospital of Split, Spinčićeva 1, 21000 Split, Croatia., Franković L; Laboratory for Cancer Research, University of Split School of Medicine, Šoltanska 2A, 21000 Split, Croatia., Korac-Prlic J; Laboratory for Cancer Research, University of Split School of Medicine, Šoltanska 2A, 21000 Split, Croatia., Terzić J; Laboratory for Cancer Research, University of Split School of Medicine, Šoltanska 2A, 21000 Split, Croatia.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Jun 29; Vol. 25 (13). Date of Electronic Publication: 2024 Jun 29.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Myeloid Differentiation Factor 88*/metabolism , Myeloid Differentiation Factor 88*/genetics , Urinary Bladder Neoplasms*/pathology , Urinary Bladder Neoplasms*/microbiology , Urinary Bladder Neoplasms*/metabolism , Urinary Bladder Neoplasms*/genetics , Signal Transduction* , Mice, Knockout* , Gastrointestinal Microbiome* , Toll-Like Receptor 4*/metabolism , Toll-Like Receptor 4*/genetics, Animals ; Mice ; Butylhydroxybutylnitrosamine/toxicity ; Carcinogenesis ; Urinary Bladder/pathology ; Urinary Bladder/microbiology ; Urinary Bladder/metabolism ; Female ; Mice, Inbred C57BL ; Microbiota ; Humans
مستخلص: Urinary bladder cancer (BC) inflicts a significant impairment of life quality and poses a high mortality risk. Schistosoma haematobium infection can cause BC, and the urinary microbiota of BC patients differs from healthy controls. Importantly, intravesical instillation of the bacterium Bacillus Calmette-Guerin stands as the foremost therapy for non-muscle invasive BC. Hence, studying the receptors and signaling molecules orchestrating bacterial recognition and the cellular response in the context of BC is of paramount importance. Thus, we challenged Toll-like receptor 4 ( Tlr4 ) and myeloid differentiation factor 88 ( Myd88 ) knock-out (KO) mice with N-butyl-N-(4-hydroxylbutyl)-nitrosamine (BBN), a well-known urinary bladder carcinogen. Gut microbiota, gene expression, and urinary bladder pathology were followed. Acute exposure to BBN did not reveal a difference in bladder pathology despite differences in the animal's ability to recognize and react to bacteria. However, chronic treatment resulted in reduced cancer invasiveness among Myd88 KO mice while the absence of functional Tlr4 did not influence BC development or progression. These differences correlate with a heightened abundance of the Faecalibaculum genus and the lowest microbial diversity observed among Myd88 KO mice. The presented data underscore the important role of microbiota composition and MyD88-mediated signaling during bladder carcinogenesis.
References: Front Immunol. 2014 Jul 31;5:367. (PMID: 25132836)
Proc Natl Acad Sci U S A. 1990 Nov;87(22):9047-51. (PMID: 2247480)
Oncogene. 2006 Aug 7;25(34):4725-43. (PMID: 16892086)
Cancer Lett. 2021 Jul 28;511:15-25. (PMID: 33945837)
Front Immunol. 2019 Oct 22;10:2388. (PMID: 31695691)
J Clin Invest. 2010 Oct;120(10):3663-7. (PMID: 20941850)
Genome Med. 2020 Oct 6;12(1):86. (PMID: 33023656)
Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18721-6. (PMID: 17130448)
Nucleic Acids Res. 2013 Jan 7;41(1):e1. (PMID: 22933715)
Sci Rep. 2020 Oct 22;10(1):18024. (PMID: 33093503)
Oncogene. 2018 Feb 1;37(5):673-686. (PMID: 29035390)
Sci Rep. 2021 Feb 17;11(1):3991. (PMID: 33597599)
FASEB J. 2020 Mar;34(3):4266-4282. (PMID: 31957111)
Int J Cancer. 2005 Feb 20;113(5):841-8. (PMID: 15499627)
J Cell Biochem. 2019 Feb;120(2):1979-1989. (PMID: 30230587)
Nat Methods. 2016 Jul;13(7):581-3. (PMID: 27214047)
BMC Cancer. 2023 Sep 7;23(1):840. (PMID: 37679666)
PLoS One. 2012;7(8):e44080. (PMID: 22952881)
Trends Cancer. 2020 Apr;6(4):277-287. (PMID: 32209443)
Nat Commun. 2020 Jul 14;11(1):3514. (PMID: 32665548)
Heliyon. 2023 Jan 16;9(1):e13012. (PMID: 36704283)
Lipids Health Dis. 2017 Nov 2;16(1):208. (PMID: 29096636)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Cell. 2013 May 9;153(4):812-27. (PMID: 23663780)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Bioinform Adv. 2024 Feb 28;4(1):vbae032. (PMID: 38464974)
PLoS Pathog. 2021 Feb 25;17(2):e1009310. (PMID: 33630958)
Sci Rep. 2023 Dec 18;13(1):22552. (PMID: 38110638)
Nat Microbiol. 2020 Mar;5(3):511-524. (PMID: 31988379)
Science. 2015 Apr 3;348(6230):80-6. (PMID: 25838377)
Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772)
CA Cancer J Clin. 2020 Sep;70(5):404-423. (PMID: 32767764)
J Clin Microbiol. 2014 Mar;52(3):871-6. (PMID: 24371246)
Sci Rep. 2018 Aug 14;8(1):12157. (PMID: 30108246)
Oncogenesis. 2023 Sep 4;12(1):44. (PMID: 37666817)
J Leukoc Biol. 2019 Jul;106(1):147-160. (PMID: 30900780)
Nature. 2011 Feb 3;470(7332):115-9. (PMID: 21179087)
Science. 2005 Mar 18;307(5716):1773-6. (PMID: 15774758)
Cancer Lett. 1996 Oct 22;107(2):241-7. (PMID: 8947520)
Nat Rev Cancer. 2020 Apr;20(4):200. (PMID: 32112044)
Nature. 2017 Nov 8;551(7679):S34-S35. (PMID: 29117159)
Diagnostics (Basel). 2021 Dec 04;11(12):. (PMID: 34943506)
Int J Cancer. 2019 Oct 15;145(8):2170-2181. (PMID: 30939216)
J Hematol Oncol. 2018 Aug 23;11(1):107. (PMID: 30139373)
Nat Rev Cancer. 2021 Feb;21(2):104-121. (PMID: 33268841)
J Clin Invest. 2022 Mar 1;132(5):. (PMID: 35229729)
Cancers (Basel). 2022 Jul 03;14(13):. (PMID: 35805035)
Cell Death Differ. 2006 May;13(5):816-25. (PMID: 16410796)
Cell Host Microbe. 2017 Jan 11;21(1):7-10. (PMID: 28081445)
Cell Host Microbe. 2022 Aug 10;30(8):1066-1069. (PMID: 35952642)
Int J Urol. 2008 May;15(5):435-41. (PMID: 18452462)
J Urol. 2011 May;185(5):1915-21. (PMID: 21421234)
Signal Transduct Target Ther. 2017;2:. (PMID: 29158945)
Front Cell Infect Microbiol. 2024 Apr 08;14:1374944. (PMID: 38650736)
JAMA. 2020 Nov 17;324(19):1980-1991. (PMID: 33201207)
Nat Biotechnol. 2019 Aug;37(8):852-857. (PMID: 31341288)
Trends Immunol. 2013 Aug;34(8):379-89. (PMID: 23660392)
معلومات مُعتمدة: IP-2020-02-8921 Croatian Science Foundation; DOK-2021-02 Croatian Science Foundation
فهرسة مساهمة: Keywords: Faecalibaculum; Toll-like receptor 4; microbiota; myeloid differentiation factor 88; urinary bladder neoplasms
المشرفين على المادة: 0 (Myeloid Differentiation Factor 88)
0 (Toll-Like Receptor 4)
0 (Myd88 protein, mouse)
3817-11-6 (Butylhydroxybutylnitrosamine)
0 (Tlr4 protein, mouse)
تواريخ الأحداث: Date Created: 20240713 Date Completed: 20240713 Latest Revision: 20240715
رمز التحديث: 20240715
مُعرف محوري في PubMed: PMC11241070
DOI: 10.3390/ijms25137176
PMID: 39000291
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25137176